In this study, 100 patients with type 2 diabetes, previously treated with OADs (with or without basal insulin), were initiated with, or switched basal insulin therapy to, BIAsp 30 OD for 16 weeks. The gene discussed is INS; the disease is type 2 diabetes mellitus.